BMEA Biomea Fusion
- 12.330
- +0.400+3.35%
Biomea Fusion News
Biomea Fusion Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Repligen (RGEN) and Agenus (AGEN)
Barclays Sticks to Its Buy Rating for Biomea Fusion (BMEA)
Biomea Fusion Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Biomea Fusion (BMEA) and GoodRx Holdings (GDRX)
Biomea Fusion (BMEA) Receives a Buy From Scotiabank
Analysts Offer Insights on Healthcare Companies: Humana (HUM), Baxter International (BAX) and Biomea Fusion (BMEA)
Buy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Results and Strong Financial Position
Truist Securities Reiterates Buy on Biomea Fusion, Maintains $55 Price Target
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Intuitive Surgical (ISRG) and Sangamo Biosciences (SGMO)
Truist Financial Issues a Buy Rating on Biomea Fusion (BMEA)
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)
Analysts Are Bullish on These Healthcare Stocks: RegenXBio (RGNX), Biomea Fusion (BMEA)
Buy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Trial Outcomes and Strong Safety Profile
Biomea Fusion Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $50 Price Target
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Gritstone Oncology (GRTS) and Organon (OGN)
Truist Securities Initiates Coverage On Biomea Fusion With Buy Rating, Announces Price Target of $55
Analysis
Price Target
No Data
